全球生物制药巨头默沙东公司(Merck)于2024年8月9日宣布了一项重大战略收购,正式达成了对上海同润生物(Curon Biopharmaceutical)开发的CD3xCD19双特异性抗体CN201的最终收购协议。此笔交易规模可能高达13亿美元,标志着默沙东在扩大其肿瘤治疗产品组合...
“This agreement reflects the drive and dedication of the Curon team,” saidZhihong Chen, president and chief executive officer, Curon. “As a pioneer in immuno-oncology,Merckis well positioned to build upon the work done to-date and investigate the wide-ranging, first-in-class potential of C...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Curon Biopharmaceutical (Curon), a privately held biotechnology company, today announced that the companies have entered into adefinitiveagreement under which Merck, through a subsidi...
全球生物制药巨头默沙东公司(Merck)于2024年8月9日宣布了一项重大战略收购,正式达成了对上海同润生物(Curon Biopharmaceutical)开发的CD3xCD19双特异性抗体CN201的最终收购协议。此笔交易规模可能高达13亿美元,标志着默沙东在扩大其肿瘤治疗产品组合...